We claim:

1. A pharmaceutical composition comprising a combination consisting of a pure 5-HT_6 receptor antagonist and an NMDA receptor antagonist, wherein the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof, and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

4. The pharmaceutical composition as claimed in any one of claims 1 to 3, wherein the NMDA receptor antagonist is memantine hydrochloride.

5. A pharmaceutical composition comprising a combination consisting of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and memantine hydrochloride.

6. The pharmaceutical composition as claimed in any one of claims 1 to 5, for use in the treatment of cognitive disorders in a patient.

7. Use of the pharmaceutical composition as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of cognitive disorders in a patient, wherein the cognitive disorders are selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

8. Use of a combination consisting of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or pharmaceutically acceptable salt thereof and an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

9. Use of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for adjunct treatment of Alzheimer's disease in a patient on stable treatment with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

10. The use as claimed in claim 8 or claim 9, wherein the 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

11. The use as claimed in claim 8 or claim 9,
(a) wherein 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or

(b) wherein 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(c) wherein 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(d) wherein 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(e) wherein 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(f) wherein 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day; and
(g) wherein 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(h) wherein 5 mg to 28 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

12. The use as claimed in claim 8 or claim 9, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

13. The use as claimed in claim 8, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.

14. The pharmaceutical composition as claimed in any one of claims 1 to 5, and pharmaceutically acceptable excipients.

15. The pharmaceutical composition and pharmaceutically acceptable excipients as claimed in claim 14, for use in the treatment of cognitive disorder selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

16. The pharmaceutical composition and pharmaceutically acceptable excipients as claimed in claim 14 or the pharmaceutical composition and pharmaceutically acceptable excipients for use as claimed in claim 15,
(a) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg, or
(b) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg, or
(c) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg, or
(d) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg or 125 mg; and
(e) wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 5 mg to 40 mg.

17. Use of a combination consisting of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or pharmaceutically acceptable salt thereof and an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cognitive disorders, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

18. Use of the pharmaceutical composition as claimed in any one of claims 1 to 5, and pharmaceutically acceptable excipients in the manufacture of a medicament for the treatment of cognitive disorders.